ArticleActa pharmacologica Sinica2024
SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson's disease.
Wei Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this paperpooled itcites it